Xenetic Biosciences Inc XBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
-
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
-
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.72–1.90
- 52-Week Range
- $1.72–4.94
- Bid/Ask
- $1.58 / $2.57
- Shares Outstanding
- 2.34M
- Market Cap
- $4.03M
- Volume/Avg
- 22,122 / 85,911
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.10
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.xeneticbio.com
Valuation
|
Metric
|
XBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.66 |
Price/Sales | 1.10 |
Price/Cash Flow | — |
Price/Earnings
XBIO
Financial Strength
|
Metric
|
XBIO
|
|---|---|
Quick Ratio | 7.23 |
Current Ratio | 7.43 |
Interest Coverage | — |
Quick Ratio
XBIO
Profitability
|
Metric
|
XBIO
|
|---|---|
Return on Assets (Normalized) | −35.38% |
Return on Equity (Normalized) | −41.33% |
Return on Invested Capital (Normalized) | −44.13% |
Return on Assets
XBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|hCVf>! | LOCK|xvtT# | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|H@^crT | LOCK|bc%@ | $83B | |||
| Moderna Inc
MRNA
| LOCK|?b@@@! | LOCK|^NS | $80B | |||
| argenx SE ADR
ARGX
| LOCK|ksJ?!x | LOCK|cL | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?x!q^w | LOCK|XH | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Zt>Y>tk | LOCK|W@wGx | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pGzb$$Qm | LOCK|^rSv | $28B | |||
| Incyte Corp
INCY
| LOCK|#RW&%T | LOCK|$mV | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^NlSxzd | LOCK|bQQ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|KQkLK#J | LOCK|yM | $14B |
United States